Foundation Medicine Expands Collaboration With Bristol Myers To Develop Foundationone Cdx As Next-Gen Sequencing Companion Diagnostic To Identify Patients With Homozygous MTAP Deletionin

Foundation Medicine, Inc., a global precision medicine company, today announced an expansion to its collaboration with Bristol Myers Squibb (NYSE:BMY) to develop FoundationOne®CDx as a next-generation

Bristol Myers Squibb Licenses Five Drug Programs To New Biotech Beeline Medicines

Beeline Medicines Corporation ("Beeline Medicines" or "the Company"), a clinical-stage biotechnology company, today announced its official debut with the mission of developing and delivering category-leading precision

March Inflation Set For Biggest Jump Since June 2022 — When CPI Spikes, These Stocks Fall

Trump, in January, said "inflation has been defeated." Wall Street is now bracing for a 0.9% monthly CPI surge — the steepest since June 2022.

B of A Securities Maintains Buy on Bristol-Myers Squibb, Lowers Price Target to $67

B of A Securities analyst Tim Anderson maintains Bristol-Myers Squibb (NYSE:BMY) with a Buy and lowers the price target from $68 to $67.

Oxford BioTherapeutics Teams Up With Bristol Myers Squibb To Develop New Cancer Treatments

Oxford BioTherapeutics ("OBT"), is a clinical stage oncology company focused on the discovery and development of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based therapies enabled by its OGAP®-Verify

MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst

Needham initiates MapLight with Buy, citing ML-007C-MA potential in schizophrenia and AD psychosis, with key readouts expected through 2027.

Guggenheim Reiterates Buy on Bristol-Myers Squibb, Maintains $72 Price Target

Guggenheim analyst Seamus Fernandez reiterates Bristol-Myers Squibb (NYSE:BMY) with a Buy and maintains $72 price target.

Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $54

Cantor Fitzgerald analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and raises the price target from $45 to $54.

Janux Therapeutics Nominates Development Candidate Under Collaboration, License Agreement With Bristol Myers Squibb

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate under its

Reported Saturday, Bristol Myers Squibb's Phase 4 Trial Shows 86% Treatment Completion And No Efficacy Discontinuations When Switching Schizophrenia Patients To Cobenfy Over 8 Weeks

Reported Sunday, Bristol Myers Squibb's Phase 3 SCOUT-HCM Trial Of Camzyos Meets Primary Endpoint In Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Trial met its primary endpoint, demonstrating clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28Results demonstrate the potential for